drugset

drugset / Trial / NCT06535685

A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA

NCT06535685 ↗

Phase 4 Not yet recruiting 40 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

Summary

Efficacy and safety of Romiplostim in the treatment of refractory transfusion-dependent NSAA.

Timeline

Start: 2024-08-02
Primary completion: 2025-03-30
Completion: 2025-12-31

Publications

Background Young NS. Aplastic anaemia. Lancet. 1995 Jul 22;346(8969):228-32. doi: 10.1016/s0140-6736(95)91273-8. No abstract available.
Background Young NS. Aplastic Anemia. N Engl J Med. 2018 Oct 25;379(17):1643-1656. doi: 10.1056/NEJMra1413485. No abstract available.
Background Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017 Mar 16;129(11):1428-1436. doi: 10.1182/blood-2016-08-693481. Epub 2017 Jan 17.
Background Yang C, Zhang X. Incidence survey of aplastic anemia in China. Chin Med Sci J. 1991 Dec;6(4):203-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Romiplostim	Peptide	20 ug/kg	Subcutaneous

Indications